NVCR / Novocure Stock: Bull vs. Bear

The cancer treatment device developer released its latest set of quarterly results. These were a mixed bag, as it notched a beat on earnings but misse more_horizontal

NovoCure doesn't have any direct competitors for its anti-cancer device. The product could see its indications expanded into various other niches. more_horizontal

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and pot more_horizontal

One of NovoCure's late-stage clinical trials didn't turn out well. There are serious questions about the cost effectiveness of its product. more_horizontal

On Monday, Novocure announced a key phase 3 trial evaluating its Tumor Treating Fields (TTFields) therapy in treating platinum-resistant ovarian cance more_horizontal

NovoCure's treatment for ovarian cancer failed to prove it was effective in a late-stage trial. It's a big blow for a company whose business isn't in more_horizontal

Novocure (NVCR) shares plunged 37.5% on Monday after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields more_horizontal

Shares of innovative biotechnology firm Novocure (NASDAQ: NVCR ) cratered badly, losing 30% on Monday morning before fading even further in the early more_horizontal